Summary
Four women with metastatic breast carcinoma and elevated plasma levels of human breast gross cystic disease fluid protein of 15,000 dalton monomer size (GCDFP-15) were treated IV with non-human primate (baboon) anti-GCDFP-15 antibody. Three patients were given a single IV infusion of antibody, while the fourth patient received four sequential IV infusions. Antibody dosage patients, after antibody infusion the plasma level of GCDFP-15 decreased to 0 ng/ml and remained there as long as “free” circulating anti-GCDFP-15 antibody was present. The plasma half-life of the antibody ranged between 1 and 40 h and the duration of detectable free antibody ranged from 6 to 240 h. No toxicity was observed for the dosage range of antibody tested. No anti-baboon antibody response was detected. In the patient who received four sequential infusions of antibody partial regression of subcutaneous metastatic nodules occurred. The other three patients showed no clinically detectable changes from the antibody infusion.
Similar content being viewed by others
References
Goodman GE, Beaumier P, Hellstrom I, Fernyhough B, Hellstrom KE (1980) Pilot trial of murine monoclonal antibodies in patients with advanced melanoma. J Clin Oncol 3:340
Haagensen DE Jr, Mazoujian G (1986) Biochemistry and immunohistochemistry of fluid proteins of the breast in gross cystic disease: In: Haagensen CD (ed) Diseases of the breast. Saunders Publishing Co., Philadelphia, p 474
Haagensen DE Jr, Easterday RL, Stolle CA, Wells SA Jr (1978) Buffer exchange column for rapid separation of carcinoembryonic antigen from erchloric acid. Clin Chem 24:135
Haagensen DE Jr, Kister SJ, Panick J, Giannola J, Hansen HJ, Wells SA Jr, (1978) Comparative evaluation of carcinoembryonic antigen and gross cystic disease fluid protein as plasma markers for human breast carcinoma. Cancer 42:1646
Haagensen DE Jr, Mazoujian G, Dilley WG, Peterson CE, Kister SJ, Wells SA Jr (1979) Gross cystic disease fluid analysis: I. Isolation and radioimmunoassay for a major component protein. J Natl Cancer Inst 62:239
Haagensen DE Jr, Wells SA Jr, Haider M (1980) Analysis of human breast gross cystic disease fluid protein (GCDFP) by isotope dilution radioimmunoassay with solid phase (Kynar) second antibody. Proc Am Clin Chem 26:980
Hansen HJ, Lance KP, Krupey J (1971) Demonstration of an ion sensitive antigen site on carcinoembryonic antigen using zirconyl phosphate gel. Clin Res 19:53
Houghton AN, Mintzer D, Cordon-Cardo C, Welt S, Fiegel B, Vadhan S, Carswell E, Melamed MR, Oettgen HF, Old LJ (1985) Mouse monoclonal IgG3 antibody detecting GA3 ganglioside: A phase I trial in patients with malignant melanoma. Proc Natl Acad Sci USA 82:1242
Mazoujian G, Pinkus GS, Davis S, Haagensen DE Jr (1973) Immunohistochemistry of a gross cystic disease fluid protein (GCDFP-15) of the breast. Am J Pathol 110:105
Miller RA, Maloney DG, Warnke R, Levy R (1982) Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 306:517
Rolosen GJ, Haagensen DE Jr, Chambers CA, Bolognesi DP (1981) Immunological control of the ascites form of murine adenocarcinoma 755: III efficacy of serum therapy is controlled by a single genetic locus. J Immunol 126:2328
Sears HF, Mattis J, Herlyn D, Hayry P, Atkinson B, Ernst C, Steölewski Z, Kopowski H (1984) Phase I clinical trial of monoclonal antibody in treatment of gastrointestinal tumors. Lancet 762
Shuster J, Warner NL, Fudenberg HH (1969) Cross-reactivity of primate immunoglobulins. Ann NY Acad Sci 162:195
Sullivan EC, Silva JS, Cox CE, Haagensen DE, Jr., Harris CC, Briner WH, Wells SA Jr (1982) Localization of 125I-labelled goat and primate anticarcinoembryonic antigen antibodies in patient with cancer. Invest Radiol 17:350
Author information
Authors and Affiliations
Additional information
Funded in part by a grant from the William J. Matheson Foundation
Rights and permissions
About this article
Cite this article
Estabrook, A., Kister, S.J., Hardy, M.A. et al. Non-human primate (baboon) anti-gross cystic disease fluid protein-15 antibody infusion in four women with metastatic breast carcinoma. Cancer Immunol Immunother 23, 143–147 (1986). https://doi.org/10.1007/BF00199821
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00199821